Treating Fungal Keratitis with Oral Voriconazole Only: A Case Series

Abstract

Background To report the clinical effect of oral voriconazole only as a treatment for fungal keratitis.

History and Signs Three patients (1 female and 2 males) with culture-proven fungal keratitis (1 Mucoraceae, 1 Aspergillus, 1 Fusarium) were included in this study. The patients were treated with oral voriconazole 200 mg twice daily to observe the clinical response in the treatment of fungal keratitis.

Therapy and Outcome The mean age of the patients was 51 years and the average treatment duration was 6 weeks. The corneal inflammation in these three patients was eliminated by oral voriconazole only.

Conclusions This is the first reported case of oral voriconazole only as a treatment for fungal keratitis. We found that oral voriconazole has a significant clinical effect on the treatment of fungal keratitis.

Zusammenfassung

Hintergrund Berichterstattung über die klinische Wirkung von oralem Voriconazol zur Behandlung von Pilzkeratitis.

Anamnese und Befunde Insgesamt wurden 3 konsekutive Patienten (1 Frau, 2 Männer) mit gesicherter Pilzkeratitis (1 mit Mucoraceae, 1 mit Aspergillus, 1 mit Fusarium) in diese Studie eingeschlossen. Die Patienten wurden 2 × täglich mit 200 mg oralem Voriconazol behandelt, um das klinische Ansprechen bei der Behandlung der Pilzkeratitis zu beobachten.

Therapie und Verlauf Das Durchschnittsalter der Patienten betrug 51 Jahre und die durchschnittliche Behandlungsdauer 6 Wochen. Die Hornhautentzündung bei diesen 3 Patienten wurde nur durch orales Voriconazol beseitigt.

Schlussfolgerungen Dies ist der erste Bericht, bei dem nur orales Voriconazol zur Behandlung von Pilzkeratitis verwendet wird. Wir fanden heraus, dass orales Voriconazol einen signifikanten klinischen Effekt auf die Behandlung von Pilzkeratitis hat.

Key words

microbiology - trauma - cornea

Schlüsselwörter

Kornea - Mikrobiologie - Trauma

Publication History

Received: 01 August 2020

Accepted: 03 September 2020

Article published online:
18 December 2020

• References

• 1 Niu L, Liu X, Ma Z. et al. Fungal keratitis: Pathogenesis, diagnosis and prevention. Microb Pathog 2020; 138: 103802
• 2 Hariprasad SM, Mieler WF, Lin TK. et al. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008; 92: 871-878
• 3 Thomas PA. Current perspectives on ophthalmic mycoses. Clin Microbiol Rev 2003; 16: 730-797 doi:10.1128/cmr.16.4.730-797.2003
• 4 Marangon FB, Miller D, Giaconi JA. et al. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 2004; 137: 820-825
• 5 Shah KB, Wu TG, Wilhelmus KR. et al. Activity of voriconazole against corneal isolates of Scedosporium apiospermum. Cornea 2003; 22: 33-36
• 6 Patterson TF, Boucher HW, Herbrecht R. et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41: 1448-1452 doi:10.1086/497126
• 7 Hariprasad SM, Mieler WF, Holz ER. et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122: 42-47 doi:10.1001/archopht.122.1.42
• 8 Premamalini T, Ambujavalli BT, Vijayakumar R. et al. Fungal keratitis caused by Macrophomina phaseolina – A case report. Med Mycol Case Rep 2012; 1: 123-126
• 9 Khochtali S, Hriz A, Abid F. et al. Alternaria keratitis after uneventful phacoemulsification in an otherwise healthy adult. J Ophthalmic Inflamm Infect 2016; 6: 4 doi:10.1186/s12348-016-0072-5
• 10 Li STL, Yiu EPF, Wong AHY. et al. Successful Treatment of Lasiodiplodia theobromae keratitis – Assessing the Role of Voriconazole. Case Rep Ophthalmol 2016; 7: 179-185
• 11 Bongomin F, Gago S, Oladele RO. et al. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel) 2017; 3: 57 doi:10.3390/jof3040057
• 12 Watson SL, Cabrera-Aguas M, Keay L. et al. The clinical and microbiological features and outcomes of fungal keratitis over 9 years in Sydney, Australia. Mycoses 2020; 63: 43-51
• 13 Durand ML, Kim IK, DʼAmico DJ. et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 2005; 140: 552-554
• 14 Sharma N, Singhal D, Maharana PK. et al. Comparison of oral voriconazole versus oral ketoconazole as an adjunct to topical natamycin in severe fungal keratitis. Cornea 2017; 36: 1521-1527
• 15 Garbino J, Ondrusova A, Baligvo E. et al. Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole. Scand J Infect Dis 2002; 34: 701-703
• 16 Kim JE, Perkins SL, Harris GJ. Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection. Arch Ophthalmol 2003; 121: 735-737 doi:10.1001/archopht.121.5.735